Literature DB >> 18276906

Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction.

Marianne Zeller1, Claudia Korandji, Jean-Claude Guilland, Pierre Sicard, Catherine Vergely, Luc Lorgis, Jean-Claude Beer, Laurence Duvillard, Anne-Cécile Lagrost, Daniel Moreau, Philippe Gambert, Yves Cottin, Luc Rochette.   

Abstract

OBJECTIVE: Asymmetrical dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthases. From a prospective cohort of patients with acute myocardial infarction (MI), we aimed to analyze the predictive value of circulating ADMA concentrations on prognosis. METHODS AND
RESULTS: Blood samples from 249 consecutive patients hospitalized for acute MI <24 hours were taken on admission. Serum levels of ADMA and its stereoisomer, symmetrical dimethylarginine (SDMA), were determined using high-performance liquid chromatography. The independent predictors of ADMA were glomerular filtration rate, female sex, and SDMA (R(2)=0. 25). Baseline ADMA levels were higher in patients who had died than in patients who were alive at 1 year follow-up (1.23 [0.98 to 1.56] versus 0.95 [0.77 to 1.20] micromol/L, P<0.001). By Cox multivariate analysis, the higher tertile of ADMA (median [interquartile range]: 1.45 [1.24 to 1.70] micromol/L) was a predictor for mortality (Hazard Ratio [95% CI], 4.83 [1.59 to 14.71]), when compared to lower tertiles, even when adjusted for potential confounders, such as acute therapy, biological, and clinical factors.
CONCLUSIONS: Our study suggests that the baseline ADMA level has a strong prognostic value for mortality after MI, beyond traditional risk factors and biomarkers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18276906     DOI: 10.1161/ATVBAHA.108.162768

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  30 in total

1.  Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1.

Authors:  Zhili Shao; Zeneng Wang; Kevin Shrestha; Akanksha Thakur; Allen G Borowski; Wendy Sweet; James D Thomas; Christine S Moravec; Stanley L Hazen; W H Wilson Tang
Journal:  J Am Coll Cardiol       Date:  2012-03-27       Impact factor: 24.094

2.  Asymmetric Dimethylarginine Predicts One-year Recurrent Cardiovascular Events: Potential Biomarker of "Toxin Syndrome" in Coronary Heart Disease.

Authors:  Hao Xu; Zhuo Chen; Qing-Hua Shang; Zhu-Ye Gao; Chang-An Yu; Da-Zhuo Shi; Ke-Ji Chen
Journal:  Chin J Integr Med       Date:  2019-05-07       Impact factor: 1.978

3.  Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.

Authors:  Eva Schepers; Daniela V Barreto; Sophie Liabeuf; Griet Glorieux; Sunny Eloot; Fellype C Barreto; Ziad Massy; Raymond Vanholder
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 8.237

Review 4.  [Asymmetric dimethylarginine (ADMA): A cardiovascular risk factor].

Authors:  Friedrich Mittermayer; Katarzyna Krzyzanowska; Michael Wolzt
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

5.  Elevated preoperative serum asymmetrical dimethylarginine (ADMA) is associated with poor outcomes after pediatric cardiac surgery.

Authors:  Amanda B Hassinger; Mark S Wainwright; Jerome C Lane; Shannon Haymond; Carl L Backer; Eric Wald
Journal:  Intensive Care Med       Date:  2012-08-09       Impact factor: 17.440

6.  Heat-assisted extraction for the determination of methylarginines in serum by CE.

Authors:  Thomas H Linz; Susan M Lunte
Journal:  Electrophoresis       Date:  2013-06       Impact factor: 3.535

7.  Value and level of circulating endothelial progenitor cells, angiogenesis factors and mononuclear cell apoptosis in patients with chronic kidney disease.

Authors:  Yen-Ta Chen; Ben-Chung Cheng; Sheung-Fat Ko; Chih-Hung Chen; Tzu-Hsien Tsai; Steve Leu; Hsueh-Wen Chang; Sheng-Ying Chung; Sarah Chua; Kuo-Ho Yeh; Yung-Lung Chen; Hon-Kan Yip
Journal:  Clin Exp Nephrol       Date:  2012-07-20       Impact factor: 2.801

8.  The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.

Authors:  Latika Sibal; Sharad C Agarwal; Philip D Home; Rainer H Boger
Journal:  Curr Cardiol Rev       Date:  2010-05

9.  Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

Authors:  Jill Melendez Young; Norma Terrin; Xuelei Wang; Tom Greene; Gerald J Beck; John W Kusek; Allan J Collins; Mark J Sarnak; Vandana Menon
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 8.237

10.  Endothelial dysfunction, inflammation and malnutrition markers as predictors of mortality in dialysis patients: multimarker approach.

Authors:  Aleksandra M Ignjatović; Tatjana P Cvetković; Radmila M Pavlović; Vidojko M Đorđević; Zoran G Milošević; Vidosava B Đorđević; Dušica D Pavlović; Ivana R Stojanović; Dragan Bogdanović
Journal:  Int Urol Nephrol       Date:  2013-04-17       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.